AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 151 min read$CYTK

Blum Robert I sold $528K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $70.46 ($0.53M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Jun 15, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale of 7,500 shares at a stated price, with holdings after the trade and confirmation of a 10b5-1 plan.

02

Market read

This is a fresh insider-sale datapoint that may influence short-term sentiment, but it lacks any fundamental catalyst in the text.

03

What to watch

Traders may overreact to insider sales; without concurrent news (earnings, trial readouts, financing, or guidance), the disclosure is unlikely to change fundamental valuation.

Relevance 4/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-15 (same day as transaction)

Background

The filing is an SEC Form 4 insider transaction for CYTOKINETICS, reported by the company’s President & CEO.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOKINETICS CEO Robert I. Blum sold 7,500 shares in an open-market transaction at $70.4600 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction is more about signaling than fundamentals given the 10b5-1 structure.

Evidence & confidence

The article provides only the insider sale details (size, price, post-transaction holdings) with no accompanying operational or financial catalyst; 10b5-1 typically reduces interpretive weight.

Market effects

Sector

Minimal; this is company-specific insider transaction disclosure with no sector-wide regulatory/clinical/contract signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Issuer of the insider transaction; subject of the SEC Form 4 disclosure.

  • insider
    Blum Robert I

    President & CEO who executed the reported sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

AUG 28
MedAI 9/10

Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics reported $25.3M in MYQORZO sales for Q2, with 700+ healthcare providers prescribing it. Armistice Capital increased its stake by 57% to 1.2M shares. The company plans to submit a supplemental drug application for non-obstructive HCM in Q4 2026. Total revenue fell to $28.6M from $66.8M YoY due to lower collaboration payments. Cytokinetics ended Q2 with $1.7B in cash and investments.

punchng.com2 min
AUG 28
$CYTKMedAI 8/10

Why Cytokinetics (CYTK) Stock Is Down Today

Cytokinetics (CYTK) shares fell 7.7% following the release of full Phase 3 ACACIA-HCM trial data for aficamten, which met primary endpoints but showed treatment interruptions and adverse events. The next milestone is a 2026 FDA filing. Investors may have already priced in positive topline results from May.

quiverquant.com2 min
AUG 28
$CYTKMedAI 8/10

CYTK Looks 64.3% Undervalued on GF Value™ Despite Profitability

Cytokinetics Inc (CYTK) saw its stock decline after detailed Phase 3 trial data for Myqorzo was released. The company plans to file an FDA application in Q4 2026. CYTK trades at a high P/S ratio of 136.11, with a GF Value™ suggesting it is 64.3% undervalued. The GF Score™ is 51/100, indicating moderate fundamentals with weak profitability and financial strength. Insiders have sold $43.7M in shares, while 8 gurus hold positions, with mixed activity.

gurufocus.com3 min
AUG 14
$CAPRMedAI 8/10

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.

finance.yahoo.com4 min
AUG 13
$CYTKMedAI 8/10

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.

fool.com10 min
AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstruc

SEC EDGAR 8-K6 min